3 completed, 1 active not recruiting, 1 recruiting, 1 withdrawn. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
Follow Recurrent Glioblastoma: new trials by email Literature Review of Recurrent Glioblastoma trials Research Report on Recurrent Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM SonoCloud-9 (SC9), Carboplatin, Lomustine - Glioblastoma, Recurrent Glioblastoma | Phase 3 | Recruiting | CarThera | 560 | 2024-01-29 | 2026-10-05 |
| Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM ASC40 tablets, Placebo tablets, Bevacizumab - Recurrent Glioblastoma | Phase 3 | Active not recruiting | Ascletis Pharmaceuticals Co., Ltd. | 136 | 2022-01-21 | 2024-10-31 |
| Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma ChemoID assay, Chemotherapy - Recurrent Glioblastoma | Phase 3 | Completed | Cordgenics, LLC | 78 | 2018-05-20 | 2025-04-15 |
| A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Nivolumab, Bevacizumab, Ipilimumab - Recurrent Glioblastoma | Phase 3 | Completed | Bristol-Myers Squibb | 529 | 2014-02-07 | 2025-04-04 |
| A Phase III Study of Re-Irradiation in Recurrent Glioblastoma TMZ plus concurrent re-irradiation, Temozolomide - Recurrent Glioblastoma | Phase 3 | Withdrawn | AHS Cancer Control Alberta | 2014-02-01 | 2016-03-16 | |
| Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Cediranib, Lomustine Chemotherapy, Placebo Cediranib - Recurrent Glioblastoma | Phase 3 | Completed | AstraZeneca | 423 | 2008-10-01 | 2016-12-28 |
Glioblastoma (6) · Brain Neoplasms (1) · Neoplasms (1)
Astrocytoma (6) · Glioma (6) · Neoplasms by Histologic Type (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neoplasms, Neuroepithelial (6) · Neuroectodermal Tumors (6) · Neoplasms (5) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Bevacizumab (2) · Temozolomide (2) · Carboplatin (1) · Drug Therapy (1) · Ipilimumab (1) · Lomustine (1) · Nivolumab (1) · TVB-2640 (1) · cediranib (1)
AHS Cancer Control Alberta (1) · Ascletis Pharmaceuticals Co., Ltd. (1) · AstraZeneca (1) · Bristol-Myers Squibb (1) · CarThera (1) · Cordgenics, LLC (1)
United States (4) · Belgium (3) · France (3) · Germany (3) · Netherlands (3) · Australia (2) · Austria (2) · Canada (2) · Denmark (2) · Italy (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · China (1) · Czechia (1)
Gerald Lim, MD (1) · Jane Robertson (1) · Samir Patel, MD (1) · Tracy Batchelor, MD, MPH (1) · Tulika Ranjan, MD (1)
PMID 23940216, PMID 30522968, PMID 32437507, PMID 32691060, PMID 37137304, PMID 39777725, PMID 40404984
2023 (1)